Category: Accuray Inc.
Accuray CEO Euan Thomson discusses the finer points of robotic prostate cancer treatment and the motivation behind a head-to-head clinical trial pitting its CyberKnife radiosurgery system against Intuitive Surgical's da Vinci.
Early results from a 10-year follow-up of prostate cancer treatment suggests that prostatectomy offers minimal survival benefits compared with the "wait and see" approach in certain patients.
Early results from a long-term study of prostate cancer patients concluded that removal of the gland barely increased the likelihood for survival in patients with low-risk tumors, concluding that the surgical approach "may be neither necessary nor effective."
Boston Scientific warns on ICD electrical malfunctions in a pair of ICDs following 1 patient's death; device tax opposition forces seem to be gaining steam; HeartWare wins an FDA panel nod for its heart pump; analysts are cautious about Boston Scientific's $1.3B lead-free ICD ahead of an FDA panel; Accuray's CyberKnife plans to go head-to-head against Intuitive's da Vinci robot; a Senate panel adds safety measures to FDA's user fee act; and exposed FDA docs reveal misgivings about the EU's device review system.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.
HeartWare wins an FDA panel nod for its HVAD heart pump, Accuray's CyberKnife goes head-to-head against Intuitive's da Vinci robot and Zimmer slides on its Q1 results.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
Accuray will go head-to-head against Intuitive Surgical in a first-of-its-kind clinical study comparing its CyberKnife radiosurgery system against the da Vinci surgical robot in efforts to establish a new gold standard for early-stage prostate cancer.
Fujifilm Holdings closes its nearly $1 billion buyout of SonoSite; also, Orchid closes buyout of Sandvik's medical solutions biz; Derma Sciences drops $15M on MedEfficiency; Pentax expands endoscopy ops; Accuray signs German R&D deal; GE Healthcare plans to expand in China; and analysts' ups and downs.
Fujifilm Holdings (TSE:4901) said it closed its $54-per-share acquisition of SonoSite (NSDQ: SONO).
, Derma Sciences Inc.
, Digital Endoscopy GmbH
, FujiFilm SonoSite Inc.
, HOYA ConBio
, Johnson & Johnson
, McKesson Corp.
, Orchid Orthopedic
, University of Heidelberg
, Abbott Laboratories
, Accuray Inc.
, Allergan Inc.
, Fuji Medical Systems USA
, GE Healthcare
Accuray CEO Euan Thomson tells MassDevice about being a small fish in a big pond, managing growing pains and his strategies for breaking out in a well-established market.
When Euan Thomson landed in the corner office at radiosurgery device maker Accuray (NSDQ:ARAY) in 2002, the company was just preparing to penetrate a very well-established market.